
Last year in the UK over 60,000 cancer patients enrolled on clinical trials aimed at improving cancer treatments and making them available to all.
Please note - this trial is no longer recruiting patients. We hope to add results when they are available.
This trial is looking at a drug called givinostat to treat a blood disorder called polycythaemia vera.
Polycythaemia vera is a . This means a condition in which the
produces too many blood cells. In polycythaemia, this is too many red blood cells.
Givinostat is a drug that blocks proteins () in the body called histone deacetylases (pronounced dee-as-et-isle-azes). Cells need these to grow and divide. Blocking them may stop cancer growing. Drugs that block these enzymes are called histone deacetylase inhibitors or HDAC inhibitors.
We know from research that givinostat can help people with myeloproliferative disorders such as polycythaemia.
The aims of this trial are to find out
This trial is in 2 parts. You can join both parts of the trial if all of following apply.
To join part 1 of the trial you must also be well enough to carry out all your normal activities, apart from heavy physical work (performance status of 0 or 1) .
To join part 2 of the trial you must also be well enough to be up and about for at least half the day (performance status 0, 1 or 2).
You cannot join this trial if any of these apply. You
This trial is in 2 parts. The trial team need 24 people to join the 1st part and 28 people to join the 2nd part. Everyone will have givinostat.
In the 1st part of the trial, the first few people taking part will have a low dose of givinostat. If they don’t have any serious side effects, the next few patients will have a higher dose. And so on, until they find the best dose to give. This is called a dose escalation study.
In the 2nd part of the trial, the researchers want to find out how well givinostat works for people with polycythaemia. You have the dose that was found to be best in the first part.
Givinostat is a capsule. Your doctor will tell you how many to take and how often. You can continue taking givinostat for 6 months as part of the trial.
After 6 months, you may be able to continue taking givinostat if your doctor feels it is helping you and the side effects aren’t too bad. Your doctor will talk to you about this.
The trial team will ask you to fill out a questionnaire before you start treatment, then after 3 months and 6 months. The questionnaire will ask about side effects and how you’ve been feeling. This is called a quality of life study.
In both parts of the trial, the researchers will ask for extra blood samples. They will use these to find out what happens to givinostat in your body and how it works.
If you are in the 2nd part of the trial, the researchers will ask for a sample of your bone marrow before you start treatment and after 6 months. You don’t have to agree to this. You can still take part in the trial.
You see the doctor to have some tests before taking part. These tests include
During treatment you see the doctor every 4 weeks for the same tests. You have another CT scan or MRI scan at 6 months.
At the end of the trial your doctor will tell you how often they want to see you.
The most common side effects of givinostat include
Your doctor will talk to you about the possible side effects before you take part in the trial.
Please note: In order to join a trial you will need to discuss it with your doctor, unless otherwise specified.
Professor Mary McMullin
Italfarmaco
Freephone 0808 800 4040
Last year in the UK over 60,000 cancer patients enrolled on clinical trials aimed at improving cancer treatments and making them available to all.